§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇮🇸Iceland	🇺🇸United States
Authority & dossier
Regulatory authority	IMA	FDA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	None
Reference agencies	EMA (Centralised Procedure — mirrored via EEA Joint Committee), EU/EEA Member States (DCP / MRP), EU CMDh	—
Lead pathway (timeline & fees) — EU Centralised Procedure (EEA mirror) · New Drug Application — 505(b)(1)
Pathway name	EU Centralised Procedure (EEA mirror)	New Drug Application — 505(b)(1)
Approval timeline	240–330 days	304–365 days
Application fee	EUR 350,000	USD 4,310,002
Annual renewal	EUR 130,000	USD 416,734
Local representative	Not required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	No	No
Local responsible person	Yes	Yes
RP role	QPPV established in the EEA (any EEA member) per EU GVP Module I; QPPV is the contact for IMA pharmacovigilance. Icelandic-language pharmacovigilance literature monitoring required for products marketed in Iceland. A Pharmacovigilance System Master File (PSMF) location must be declared.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	4 designations	6 designations
Examples	Accelerated Assessment (EMA CP), Conditional Marketing Authorisation (CMA), PRIME (Priority Medicines) +1	Priority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3
Post-approval lifecycle
Variations framework	EU variations framework (Commission Regulation 1234/2008 as amended) — Type IA / IAIN (do-and-tell), Type IB (tell-wait-do), Type II (prior approval), Extensions and Article 61(3) notifications. IMA processes variations for nationally / DCP / MRP authorised products; EMA processes variations for centrally-authorised products with EEA mirror in Iceland.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	Standard renewal at 5 years post first authorisation; subsequent unlimited validity unless IMA / EMA decides on safety grounds to require further renewal. CMAs renewed annually until conversion to full MA.	FDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	EU pharmacovigilance framework (Directive 2010/84/EU and Regulation 1235/2010) implemented via the Icelandic Medicinal Products Act (Lyfjalög) and IMA regulations. EudraVigilance reporting mandatory; PSURs per EURD list submitted to EMA PSUSA. Icelandic ADR reports collected by IMA via the national e-reporting portal (for healthcare professionals and consumers). Iceland participates as observer at PRAC. Strong epidemiological surveillance is enabled by Iceland's near-complete population health registers (the Icelandic National Patient Register, the Prescription Medicines Register, and population-wide kennitala-linkable records — among the most comprehensive globally for a defined small population).	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60–106 days	30–30 days
GCP standard	ICH E6(R3) GCP; EU Clinical Trials Regulation 536/2014 (EU CTR); Icelandic Medicinal Products Act and Act on Scientific Research in the Health Sector (Lög um vísindarannsóknir á heilbrigðissviði nr. 44/2014)	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Regulated	Free pricing
Reference pricing	Yes	No
HTA required	Yes	No
HTA body	Lyfjagreiðslunefnd (Drug Pricing Committee / LGN) sets maximum prices and reimbursement; HTA-style assessment increasingly informed by Nordic collaboration through FINOSE (joint Nordic HTA between Finland, Norway and Sweden, with Iceland and Denmark observing) and the EU HTA Coordination Group.	ICER (Institute for Clinical and Economic Review) — independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

IcelandIMA
United StatesFDA

English submissions

IcelandYes
United StatesYes

CTD accepted

IcelandYes
United StatesYes

eCTD accepted

IcelandYes
United StatesYes

Reliance pathway

IcelandAvailable
United StatesNone

Reference agencies

IcelandEMA (Centralised Procedure — mirrored via EEA Joint Committee), EU/EEA Member States (DCP / MRP), EU CMDh
United States—

Lead pathway (timeline & fees) — EU Centralised Procedure (EEA mirror) · New Drug Application — 505(b)(1)

Pathway name

IcelandEU Centralised Procedure (EEA mirror)
United StatesNew Drug Application — 505(b)(1)

Approval timeline

Iceland240–330 days
United States304–365 days

Application fee

IcelandEUR 350,000
United StatesUSD 4,310,002

Annual renewal

IcelandEUR 130,000
United StatesUSD 416,734

Local representative

IcelandNot required
United StatesNot required

Local manufacturing

IcelandNot required
United StatesNot required

GMP inspection

IcelandRequired
United StatesRequired

MAH & local presence

Local entity required

IcelandNo
United StatesNo

Local responsible person

IcelandYes
United StatesYes

RP role

IcelandQPPV established in the EEA (any EEA member) per EU GVP Module I; QPPV is the contact for IMA pharmacovigilance. Icelandic-language pharmacovigilance literature monitoring required for products marketed in Iceland. A Pharmacovigilance System Master File (PSMF) location must be declared.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

Iceland4 designations
United States6 designations

Examples

IcelandAccelerated Assessment (EMA CP), Conditional Marketing Authorisation (CMA), PRIME (Priority Medicines) +1
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3

Post-approval lifecycle

Variations framework

IcelandEU variations framework (Commission Regulation 1234/2008 as amended) — Type IA / IAIN (do-and-tell), Type IB (tell-wait-do), Type II (prior approval), Extensions and Article 61(3) notifications. IMA processes variations for nationally / DCP / MRP authorised products; EMA processes variations for centrally-authorised products with EEA mirror in Iceland.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

IcelandStandard renewal at 5 years post first authorisation; subsequent unlimited validity unless IMA / EMA decides on safety grounds to require further renewal. CMAs renewed annually until conversion to full MA.
United StatesFDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

IcelandEU pharmacovigilance framework (Directive 2010/84/EU and Regulation 1235/2010) implemented via the Icelandic Medicinal Products Act (Lyfjalög) and IMA regulations. EudraVigilance reporting mandatory; PSURs per EURD list submitted to EMA PSUSA. Icelandic ADR reports collected by IMA via the national e-reporting portal (for healthcare professionals and consumers). Iceland participates as observer at PRAC. Strong epidemiological surveillance is enabled by Iceland's near-complete population health registers (the Icelandic National Patient Register, the Prescription Medicines Register, and population-wide kennitala-linkable records — among the most comprehensive globally for a defined small population).
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

IcelandAvailable
United StatesAvailable

Compassionate Use

IcelandAvailable
United StatesAvailable

Emergency Import

IcelandAvailable
United StatesAvailable

Parallel Import

IcelandPermitted
United StatesNot permitted

Clinical trials

CTA approval

IcelandRequired
United StatesRequired

Ethics approval

IcelandYes
United StatesYes

CTA timeline

Iceland60–106 days
United States30–30 days

GCP standard

IcelandICH E6(R3) GCP; EU Clinical Trials Regulation 536/2014 (EU CTR); Icelandic Medicinal Products Act and Act on Scientific Research in the Health Sector (Lög um vísindarannsóknir á heilbrigðissviði nr. 44/2014)
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

IcelandRegulated
United StatesFree pricing

Reference pricing

IcelandYes
United StatesNo

HTA required

IcelandYes
United StatesNo

HTA body

IcelandLyfjagreiðslunefnd (Drug Pricing Committee / LGN) sets maximum prices and reimbursement; HTA-style assessment increasingly informed by Nordic collaboration through FINOSE (joint Nordic HTA between Finland, Norway and Sweden, with Iceland and Denmark observing) and the EU HTA Coordination Group.
United StatesICER (Institute for Clinical and Economic Review) — independent, non-binding